12.68 USD
-0.22 (-1.71%)
Last: Jan 30, 2026, 10:17 AM
Taking everything into account, ENTA scores 2 out of 10 in our fundamental rating. ENTA was compared to 525 industry peers in the Biotechnology industry. ENTA has a bad profitability rating. Also its financial health evaluation is rather negative. ENTA has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- ENTA had negative earnings in the past year.
- In the past year ENTA has reported a negative cash flow from operations.
- In the past 5 years ENTA always reported negative net income.
- ENTA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- ENTA's Return On Assets of -29.17% is fine compared to the rest of the industry. ENTA outperforms 67.62% of its industry peers.
- ENTA has a worse Return On Equity (-126.53%) than 61.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -29.17% | ||
| ROE | -126.53% | ||
| ROIC | N/A |
ROA(3y)-29.64%
ROA(5y)-27.87%
ROE(3y)-92.79%
ROE(5y)-67.21%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- ENTA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- ENTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for ENTA has been increased compared to 1 year ago.
- The number of shares outstanding for ENTA has been increased compared to 5 years ago.
- The debt/assets ratio for ENTA is higher compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of -1.09, we must say that ENTA is in the distress zone and has some risk of bankruptcy.
- ENTA's Altman-Z score of -1.09 is in line compared to the rest of the industry. ENTA outperforms 55.81% of its industry peers.
- ENTA has a Debt/Equity ratio of 1.74. This is a high value indicating a heavy dependency on external financing.
- The Debt to Equity ratio of ENTA (1.74) is worse than 77.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.74 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.09 |
ROIC/WACCN/A
WACC8.51%
2.3 Liquidity
- A Current Ratio of 4.21 indicates that ENTA has no problem at all paying its short term obligations.
- ENTA has a Current ratio (4.21) which is comparable to the rest of the industry.
- A Quick Ratio of 4.21 indicates that ENTA has no problem at all paying its short term obligations.
- The Quick ratio of ENTA (4.21) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.21 | ||
| Quick Ratio | 4.21 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 30.11% over the past year.
- The Revenue has decreased by -3.42% in the past year.
- ENTA shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -11.82% yearly.
EPS 1Y (TTM)30.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.03%
Revenue 1Y (TTM)-3.42%
Revenue growth 3Y-8.83%
Revenue growth 5Y-11.82%
Sales Q2Q%3.55%
3.2 Future
- The Earnings Per Share is expected to grow by 12.36% on average over the next years. This is quite good.
- ENTA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.57% yearly.
EPS Next Y18.3%
EPS Next 2Y15.48%
EPS Next 3Y11.77%
EPS Next 5Y12.36%
Revenue Next Year-2.24%
Revenue Next 2Y-1.03%
Revenue Next 3Y1.08%
Revenue Next 5Y18.57%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- ENTA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year ENTA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.48%
EPS Next 3Y11.77%
5. Dividend
5.1 Amount
- No dividends for ENTA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ENANTA PHARMACEUTICALS INC / ENTA FAQ
What is the fundamental rating for ENTA stock?
ChartMill assigns a fundamental rating of 2 / 10 to ENTA.
Can you provide the valuation status for ENANTA PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 0 / 10 to ENANTA PHARMACEUTICALS INC (ENTA). This can be considered as Overvalued.
Can you provide the profitability details for ENANTA PHARMACEUTICALS INC?
ENANTA PHARMACEUTICALS INC (ENTA) has a profitability rating of 1 / 10.